News | Heart Valve Technology | October 04, 2016

First Bioresorbable Heart Valves Implanted to Enable Cardiovascular Restoration

Three European children implanted with Xeltis bioabsorbable pulmonary heart valve in feasibility study

Xeltis bioabsorbable pulmonary heart valve, Xplore-I clinical feasibility study, first pediatric implants, EACTS 2016

October 4, 2016 — Xeltis recently announced that three pediatric patients have been successfully implanted with the world’s first heart valve enabling cardiovascular restoration. The children have been enrolled in the “Xplore-I” clinical study of the Xeltis bioabsorbable pulmonary heart valve, a multi-centered feasibility trial currently enrolling pediatric patients from 2 to 21 years of age in leading heart centers in Europe.

The primary objective of the Xplore-I clinical feasibility study is to assess the survival rate of patients undergoing right ventricular outflow tract (RVOT) reconstruction at six months following implantation of the bioabsorbable heart valve. RVOT reconstruction is an open-heart surgery often involving pulmonary heart valve replacement. It is normally performed in children born with congenital heart defects. The first three trial implants have been conducted at Gottsegen György Hungarian Institute of Cardiology’s Pediatric Cardiac Centre in Budapest (Hungary) and University Children’s Hospital in Krakow (Poland).

VIDEO: How the Xeltis Bioresorbable Pulmonary Valve Works

“The Xplore-I patients are doing well and have been discharged from hospital,” said Zsolt Prodan, M.D., head of congenital heart surgery at Paediatric Cardiac Centre in Budapest, who performed the first two interventions in July. “The bioabsorbable implant is performing according to expectations,” he added.

Prodan presented trial details at the 30th Annual Meeting of the European Association of Cardio-Thoracic Surgery (EACTS), Oct. 1-5 in Barcelona, Spain.

"Reconstruction and replacement of diseased heart valves in children using patients’ own tissue could help reduce the risk of complications and of re-interventions observed with animal and human donor implants,” stated Thierry Carrel, M.D., principal investigator of the ‘Xplore-I’ study, and professor of surgery at the Clinic for Cardiovascular Surgery, University Hospital Bern (Switzerland). “We are quite confident regarding this technology, since children from the precursor feasibility study on bio-absorbable blood vessels demonstrate excellent results over two years after implantation,” he continued.

The Xeltis bioabsorbable heart valve employs a technique known as endogenous tissue restoration (ETR). ETR is a novel therapeutic approach in cardiovascular regenerative medicine enabling the restoration within the body of complex cardiac parts with patient’s own tissue. The porous structure of a Xeltis bioabsorbable heart valve enables cardiovascular restoration by harnessing the body’s natural healing process to pervade it with new healthy tissue once implanted. As a new healthy heart valve or blood vessel made of patient’s own tissue forms around the structure of the implant and takes over functionality, the implanted valve gets absorbed in the body.

For more information: www.xeltis.com

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major